Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Kelly Kaita"'
Autor:
Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 333-349 (2016)
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naï
Externí odkaz:
https://doaj.org/article/dda945401c9c4406bf45486119425e6e
Autor:
Robert P Myers, Mel Krajden, Marc Bilodeau, Kelly Kaita, Paul Marotta, Kevork Peltekian, Alnoor Ramji, Chris Estes, Homie Razavi, Morris Sherman
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 28, Iss 5, Pp 243-250 (2014)
BACKGROUND: Chronic infection with hepatitis C virus (HCV) is a major cause of cirrhosis, hepatocellular carcinoma and liver transplantation.
Externí odkaz:
https://doaj.org/article/12e42d5b2cd04343afaf30cdb7260649
Treatment of Chronic Hepatitis C in a Canadian Aboriginal Population: Results from the Prairie Study
Autor:
Gerald Yosel Minuk, Meaghan O’Brien, Kim Hawkins, Didi Emokpare, James McHattie, Paul Harris, Lawrence Worobetz, Karen Doucette, Kelly Kaita, Stephen Wong, Gilles Pinette, Julia Uhanova
Publikováno v:
Canadian Journal of Gastroenterology, Vol 27, Iss 12, Pp 707-710 (2013)
BACKGROUND: The Aboriginal population of Canada is at increased risk of exposure to the hepatitis C virus (HCV). Previous data indicate that spontaneous clearance of HCV occurs more often in Aboriginals than Caucasians. Whether this enhanced response
Externí odkaz:
https://doaj.org/article/71d6927e268d4741acf1db553a3ef5c5
Autor:
Meaghan O’Brien, Adara Casselman, Gerry Smart, Ainsley Gretchen, Kelly Kaita, Kamran Kadkhoda
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 29, Iss 8, Pp e1-e6 (2015)
BACKGROUND: Hepatitis B virus (HBV) precore (PC) and basal core promoter (BCP) variants are well known; however, their prevalence in North America is unclear, especially among hepatitis B e antigen-negative patients.
Externí odkaz:
https://doaj.org/article/da3523b7a7214a2c8d95a792b7e2070e
Publikováno v:
Canadian Journal of Gastroenterology, Vol 27, Iss 7, Pp 414-416 (2013)
BACKGROUND: Traditional therapy with pegylated interferon and ribavirin combined with the new protease inhibitors boceprevir or telaprevir has demonstrated improved outcomes in hepatitis C virus (HCV)-infected patients. Prevalence data regarding pre-
Externí odkaz:
https://doaj.org/article/764c10f420c1461494e90725d6e24c57
Publikováno v:
Canadian Journal of Gastroenterology, Vol 14, Iss 10, Pp 851-855 (2000)
OBJECTIVE: To document and compare the outcomes of adult patients who received liver transplants for alcohol- and nonalcohol-induced liver diseases who attended a liver transplantation follow-up clinic in an urban, nontransplantation centre at a time
Externí odkaz:
https://doaj.org/article/9d8f930353654def9e1f0f82e2942623
Publikováno v:
Canadian Journal of Gastroenterology, Vol 14, Iss Suppl B, Pp 81B-82B (2000)
Data pertaining to 65 patients treated at the Health Sciences Center Hepatology Research Unit in Winnipeg, Manitoba describing local complications related to subcutaneous interferon (IFN) injection administered to treat hepatitis C virus infection ar
Externí odkaz:
https://doaj.org/article/5ae55bf0696543fa8791ace5bb397bfc
Autor:
Glen Fallows, Kelly Kaita, Gerald Minuk, Faye Penner, Gerry Smart, Magdy Dawood, Barry Rosser
Publikováno v:
Canadian Journal of Gastroenterology, Vol 14, Iss Suppl B, Pp 30B-35B (2000)
The role of hepatitis C virus (HCV) RNA quantification in determining ideal interferon (IFN) treatment of noncirrhotic HCV liver disease is uncertain. The specific aim of this study was to determine whether measurement of baseline HCV RNA or changes
Externí odkaz:
https://doaj.org/article/658a3952e03b489280b2d7851e412eb5
Autor:
Sai Krishna Gudi, Sherif Eltonsy, Joseph Delaney, Carla Osiowy, Carole Taylor, Kelly Kaita, Silvia Alessi-Severini
Publikováno v:
Canadian Liver Journal.
Background: Hepatitis-C virus (HCV) infection is a major cause of liver-related morbidity and mortality worldwide. Epidemiological data of HCV infection in the Canadian province of Manitoba are limited. Methods: A population-based retrospective study
Autor:
Nadine Kronfli, Camille Dussault, Kelly Kaita, Joseph Cox, Dennaye Fuchs, Kate Harland, Brandi Martin, Sofia Bartlett, Cindy Whitten-Nagle
Publikováno v:
Can Liver J
BACKGROUND: Delivery of hepatitis C virus (HCV) care to people in prison is essential to HCV elimination. We aimed to describe current HCV care practices across Canada’s adult provincial prisons. METHODS: One representative per provincial prison he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b09aff0ad72d791379cf490e097b907d
https://europepmc.org/articles/PMC9202774/
https://europepmc.org/articles/PMC9202774/